Michael Jaglal is an Oncology physician affiliated with University of South Florida. OpenAlex indexes 182 publications with 1,398 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-4673Provider last certified this registry record 2 Jun 2025.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20254 payments
- Alexion Pharmaceuticals, Inc.Program year20253 payments
- Janssen Scientific Affairs, LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
49.5%Opioid Agonist40.2%Oxycodone Hcl43%Oxycodone-Acetaminophen26%Morphine Sulfate Er13%Oxycontin9%Hydromorphone Hcl5%Methadone Hcl4%Part D<11 patientsBenzodiazepine3.9%Lorazepam65%Alprazolam35%Part D<11 patients+ 3 more classes in this area
Blood & clotting
22.3%Factor Xa inhibitor15.9%Eliquis66%Xarelto34%Part D≥28 patientsHemoglobin S Polymerization Inhibitor2.7%Oxbryta100%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
13.1%Antimetabolite6.8%Hydroxyurea100%Part D≥15 patientsKinase inhibitor2.1%Imbruvica100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-Analysis
Biology of Blood and Marrow Transplantation
2025 - Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Myeloid Neoplasms: A Systematic Review and Meta-Analysis
Clinical Lymphoma Myeloma & Leukemia
2025 - Geographic and Racial Disparities in Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Vogelbaum, MD
University of South Florida
Thomas Casale, MD
University of South Florida
Richard Lockey, MD
University of South Florida
Robert Hauser, MD
University of South Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”